Apr 12 |
ASLAN Pharmaceuticals GAAP EPADS of -$0.78
|
Apr 12 |
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Apr 9 |
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
|
Mar 27 |
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
|
Mar 25 |
ASLAN Pharmaceuticals files to sell 125M shares for holders
|
Mar 12 |
ASLAN Pharmaceuticals announces $5M registered direct offering
|
Mar 12 |
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
|
Mar 12 |
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
|
Mar 11 |
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
|
Mar 6 |
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
|